Registry Tracking Outcomes of Deep Brain Stimulation in Parkinson's Disease
Records outcomes of deep brain stimulation with a device in adults with Parkinson's disease.
Key facts
- Who runs it
- Boston Scientific Corporation
- Where
- Bydgoszcz, Gdansk, and Warsaw, PolandSee the 3 sitesAlso in 14 other countries, 84 sites
- Trial code
- Registry title
- Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
- Status
- Recruiting
- People taking part
- 1,500 people, planned
- Started
- 4 Mar 2014
- Expected to end
- Dec 2038
- Type of study
- Observational
- Treatments tested
- Deep Brain Stimulation (DBS)
- Record updated
- 12 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with Parkinson's disease who are treated with Boston Scientific's Vercise deep brain stimulation system. It collects real-world results.
- Age
- At least 18 years old.
- Sex
- All sexes can join.
- Disease stage
- Parkinson's disease, in people who meet the criteria in the local Vercise System Directions for Use.
Main reasons for not taking part
- Meets any contraindication in the local Vercise System Directions for Use
- Significant cognitive or psychiatric impairment may lead to exclusion from the GXT evaluation
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Meets criteria established in locally applicable Vercise System Direction for Use
- At least 18 years old
Who cannot take part
- Meets any contraindication in the Vercise System locally applicable Directions for Use; Subjects with significant cognitive or psychiatric impairment may be excluded in the evaluation of GXT
Where in Poland
Also in 14 other countries, 84 sites
- 10 Military Clinical Hospital BydgoszczBydgoszcz, PolandContact: Heleen ScholtesNo longer taking part
- Podmiot Leczniczy Copernicus Sp. z o.o.Gdansk, PolandContact: Heleen ScholtesNo longer taking part
- Centrum Onkologii Instytut im.Marii Sklodowskiej-CurieWarsaw, PolandContact: Heleen ScholtesNo longer taking part
About the trial
What the trial wants to find out
The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease.
Read full original descriptionShow less
The utilization of Image Guided Programming (IGP), and other commercially available programming features, used as planning tools for the programming of patients with Boston Scientific's Vercise DBS System are also evaluated.
Additionally, the utilization of the DBS Illumina 3D feature that may be used for the programming of patients with Boston Scientific's Vercise DBS Systems is also evaluated.
The group in the trial
- Parkinson's disease
Subjects with Parkinson's disease who will receive Vercise DBS for deep brain stimulation.
Treatment: Deep Brain Stimulation (DBS)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
- Plain-language title
- Registry Tracking Outcomes of Deep Brain Stimulation in Parkinson's DiseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 12 November 2026